TRIGGIANI, Luca
 Distribuzione geografica
Continente #
NA - Nord America 6.614
AS - Asia 2.965
EU - Europa 2.803
SA - Sud America 543
AF - Africa 61
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 12.999
Nazione #
US - Stati Uniti d'America 6.488
SG - Singapore 1.063
CN - Cina 883
IT - Italia 539
PL - Polonia 494
BR - Brasile 447
DE - Germania 432
UA - Ucraina 382
HK - Hong Kong 377
FI - Finlandia 208
VN - Vietnam 199
GB - Regno Unito 159
RU - Federazione Russa 136
TR - Turchia 128
IE - Irlanda 99
IN - India 89
FR - Francia 83
BE - Belgio 75
CA - Canada 65
BD - Bangladesh 41
ID - Indonesia 41
MX - Messico 38
CZ - Repubblica Ceca 37
AR - Argentina 33
IQ - Iraq 31
SE - Svezia 29
NL - Olanda 27
ZA - Sudafrica 27
ES - Italia 23
JP - Giappone 21
EC - Ecuador 18
AT - Austria 15
SA - Arabia Saudita 14
MA - Marocco 13
VE - Venezuela 13
CO - Colombia 12
LT - Lituania 11
UZ - Uzbekistan 11
GR - Grecia 10
AE - Emirati Arabi Uniti 8
DZ - Algeria 8
PK - Pakistan 7
AU - Australia 6
EU - Europa 6
PY - Paraguay 6
AL - Albania 5
AZ - Azerbaigian 5
IL - Israele 5
TN - Tunisia 5
AM - Armenia 4
CH - Svizzera 4
CL - Cile 4
DO - Repubblica Dominicana 4
EE - Estonia 4
HU - Ungheria 4
JM - Giamaica 4
JO - Giordania 4
KH - Cambogia 4
PE - Perù 4
PT - Portogallo 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
BY - Bielorussia 3
DK - Danimarca 3
IR - Iran 3
KG - Kirghizistan 3
KR - Corea 3
BG - Bulgaria 2
EG - Egitto 2
GD - Grenada 2
GY - Guiana 2
HN - Honduras 2
IS - Islanda 2
KE - Kenya 2
KW - Kuwait 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
NP - Nepal 2
TH - Thailandia 2
TW - Taiwan 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CR - Costa Rica 1
CY - Cipro 1
ET - Etiopia 1
GT - Guatemala 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
Totale 12.991
Città #
Ashburn 757
Fairfield 701
Singapore 518
Warsaw 486
Woodbridge 442
Hong Kong 373
Houston 346
Chandler 312
Seattle 309
Jacksonville 283
Cambridge 276
New York 257
Wilmington 243
Beijing 224
Ann Arbor 189
Los Angeles 181
Princeton 165
Helsinki 155
Dearborn 146
Dallas 141
Munich 121
Brescia 116
Istanbul 99
Dublin 96
Shanghai 76
The Dalles 76
Nanjing 74
Ho Chi Minh City 70
Leuven 60
San Francisco 50
Des Moines 49
Dong Ket 46
Moscow 45
Milan 44
Redondo Beach 42
São Paulo 41
Buffalo 39
Boardman 38
San Diego 37
Santa Clara 35
Chicago 33
Jakarta 32
Washington 32
Brno 29
Denver 29
Nanchang 29
Turku 29
London 28
Shenyang 28
Montreal 27
Orem 26
Brooklyn 25
Changsha 25
Hanoi 25
Frankfurt am Main 23
Jinan 23
Chennai 22
Poplar 21
Hebei 20
Nuremberg 20
Phoenix 20
Verona 19
Tokyo 17
Zhengzhou 17
Johannesburg 16
Kunming 16
Mexico City 16
Tianjin 16
Atlanta 15
Baghdad 15
Brussels 15
Rio de Janeiro 15
Romola 15
Toronto 15
Boston 14
Stockholm 14
Jiaxing 13
Lancaster 12
Ningbo 12
Belo Horizonte 11
New Delhi 11
Quito 11
Ribeirão Preto 11
Rome 11
Charlotte 10
Düsseldorf 10
Guangzhou 10
Kocaeli 10
Redwood City 10
Tashkent 10
Amsterdam 9
Ankara 9
Athens 9
Brasília 9
Naples 9
Buenos Aires 8
Dhaka 8
Haiphong 8
Hangzhou 8
Iseo 8
Totale 8.776
Nome #
Light and shadows of a new technique: Isphoton total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one? 241
Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cells 236
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study 233
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review 221
Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy 208
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study 208
Pros-IT CNR: an Italian prostate cancer monitoring project 206
Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy 197
A neuro-oncologic challenge: the case of a large, aggressive, malignant meningioma of the skull base with paranasal sinus involvement 193
Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group 188
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial 186
A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study) 186
Reirradiation in head and neck recurrent or second primary tumor: efficacy, safety, and prognostic factors 178
Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature 175
The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis 170
Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer 168
THE ROLE OF PRIMARY SURGERY AND EXTERNAL BEAM RADIATION THERAPY IN THE MANAGEMENT OF NON-METASTATIC DUCTAL PROSTATE CANCER: 20-YEAR OUTCOMES FROM A SINGLE INSTITUTION EXPERIENCE 167
Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature 162
Oligometastatic prostate cancer patients stratification: A molecular signature identified by liquid biopsy 162
Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines 159
Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed? 158
Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes 158
Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. 157
Role of external beam radiotherapy in the treatment of relapsing meningioma 157
Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial 156
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature 155
Reply to 'Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'' 150
Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique 150
Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program 149
Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab 148
Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further 146
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients 146
Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice 145
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO) 145
From Molecular to Clinical Radiation Biology of Glioblastoma 143
Exploring the role of enzalutamide in combination with radiation therapy: An in vitro study 143
Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study) 139
CETUXIMAB AND RADIOTHERAPY VERSUS CISPLATIN AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK CANCER: LONG TERM SURVIVAL AND TOXICITY OUTCOMES OF A RANDOMIZED PHASE II TRIAL 135
Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience 134
A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes 134
Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk. 134
GUROPA survey: genito-urinary radiation oncology prescription attitudes 133
Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy 131
Retreatment of recurrent adult medulloblastoma with radiotherapy: a case report and review of the literature. 130
Circulating Tumour Cells in Clinical Practice: Can Lessons Learned From Locally Advanced/Metastatic Breast and Prostate Cancers Guide Their use for other Cancer Types? Lights and Shadows 129
Cetuximab and Radiation Therapy in Head and Neck Cancer 129
Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study 127
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study 127
Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events 127
Stereotactic Radiation Therapy of Lung Cancers and Subsequent Parenchymal Alterations: from Their Spatial Distribution to the Use in Clinical Practice 127
Stereotactic radiotherapy with simultaneous integrated protection planning technique for synovial sarcoma with stomach abutment: A case report of a complete response 126
Radiation Tolerance of Normal Brain: QUANTEC 2010 and Beyond 125
Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repair 124
Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO) 123
The impact of tumor histology and recursive partitioning analysis classification on the prognosis of patients treated with whole-brain hypofractionated radiotherapy for brain metastases: analysis of 382 patients 119
The growing role of biology in the treatment of glioblastoma: no more one kind of disease 119
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy 119
How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study 117
Non-metastatic ductal adenocarcinoma of the prostate: pattern of care from an uro-oncology multidisciplinary group 114
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial 112
Applying radiation protection and safety in radiotherapy 111
When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients 110
Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patients 103
Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR) 101
A Systematic Review on Intensity Modulated Radiation Therapy for Mediastinal Hodgkin's Lymphoma 101
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors 100
The linguistic validation process of the Vanderbilt Head and Neck Symptom Survey - Italian Version (VHNSS-IT) 99
Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study 99
Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience 98
The “Radioresistance” of Glioblastoma in the Clinical Setting, and the Present Therapeutic Options 97
Letter to the editor regarding “Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable” 93
Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness 93
Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial 92
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment 92
Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study 87
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer 87
Health-related quality of life 24-month after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study 87
A pilot study on the Vanderbilt head and neck symptom survey Italian version (VHNSS-IT) to test its feasibility and utility in routine clinical practice 86
Effect of Degarelix administration on bone health in prostate cancer patients without bone metastases. The Blade study 84
Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study 83
Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy 80
'Le Roi est mort, vive le Roi': New Roles of Radiotherapy in the Treatment of Lymphomas in Combination With Immunotherapy 78
Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience 77
PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) 76
Stereotactic Radiotherapy for Localised Prostate Cancer: Time to Clarify the Possible Impact of Concurrent Androgen Deprivation Therapy 73
Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: A view of the nation's young oncologists 72
How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO) 71
Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in response to Onal's letter to the editor 69
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study 68
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting 67
PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study 67
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation 65
Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group 65
Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence 64
SBRT in Lymph-Nodal Oligometastases from Prostate Cancer: Different Outcomes between Pelvic and Para-Aortic Disease 62
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study) 62
Universal testing for COVID-19 in patients undergoing cancer treatment during the second outbreak in Brescia 61
High dose proton and photon-based radiation therapy for 213 liver lesions: a multi-institutional dosimetric comparison with a clinical perspective 61
Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO-Head and Neck working group 61
Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy 58
Totale 12.544
Categoria #
all - tutte 67.390
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.390


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.154 0 0 0 0 0 225 78 170 141 263 142 135
2021/2022751 65 100 26 28 12 49 31 67 39 83 38 213
2022/2023878 97 35 34 52 90 186 13 106 157 5 64 39
2023/20241.371 69 28 165 75 71 302 50 89 206 49 65 202
2024/20252.275 33 35 29 340 180 208 190 117 249 160 449 285
2025/20263.090 516 610 388 714 619 243 0 0 0 0 0 0
Totale 13.239